The added value of SLN mapping with indocyanine green in low- and intermediate-risk endometrial cancer management: a systematic review and meta-analysis

• Published in: Journal of gynecologic oncology Vol. 33; no. 5; pp. 1 - 14
• Main Authors: Lara C. Burg, Shenna Verheijen, Ruud L. M. Bekkers, Joanna Inthout, Robert W. Holloway, Salih Taskin, Sarah E. Ferguson, Yu Xue, Antonino Ditto, Glauco Baiocchi, Andrea Papadia, Giorgio Bogani, Alessandro Buda, Roy F. P. M. Kruitwagen, Petra L. M. Zusterzeel
• Format: Journal Article
• Language: Korean
• Published: 대한부인종양학회 01.09.2022
• Subjects: Endometrial Cancer; Indocyanine Green; Lymphadenectomy; Meta-Analysis; Sentinel Lymph Node Mapping; Systematic Review
• ISSN: 2005-0380

Objective: The aim of this study was to assess the SLN detection rate in presumed early stage, low- and intermediate-risk endometrial cancers, the incidence of SLN metastases, and the negative predictive value of SLN mapping performed with indocyanine green (ICG). Methods: A systematic review with meta-analyses was conducted. Study inclusion criteria were A) low- and intermediate-risk endometrial cancer, B) the use of ICG per cervical injection; C) a minimum of twenty included patients per study. To assess the negative predictive value of SLN mapping, D) a subsequent lymphadenectomy was an additional inclusion criterion. Results: Fourteen studies were selected, involving 2,117 patients. The overall and bilateral SLN detection rates were 95.6% (95% confidence interval [CI]=92.4%-97.9%) and 76.5% (95% CI=68.1%-84.0%), respectively. The incidence of SLN metastases was 9.6% (95% CI=5.1%-15.2%) in patients with grade 1-2 endometrial cancer and 11.8% (95% CI=8.1%-16.1%) in patients with grade 1-3 endometrial cancer. The negative predictive value of SLN mapping was 100% (95% CI=98.8%-100%) in studies that included grade 1-2 endometrial cancer and 99.2% (95% CI=97.9%-99.9%) in studies that also included grade 3. Conclusion: SLN mapping with ICG is feasible with a high detection rate and negative predictive value in low- and intermediate-risk endometrial cancers. Given the incidence of SLN metastases is approximately 10% in those patients, SLN mapping may lead to stage shifting with potential therapeutic consequences. Given the high negative predictive value with SLN mapping, routine lymphadenectomy should be omitted in low- and intermediaterisk endometrial cancer.